Motley Fool  Sep 22  Comment 
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.
FiercePharma  Sep 22  Comment 
Steve Miller, the chief medical officer of Express Scripts, is one of the loudest voices in the ongoing debate over high drug prices, so it was only a matter of time before he weighed in on Kymriah, Novartis’ $475,000 CAR-T treatment for some...
SeekingAlpha  Sep 20  Comment 
SeekingAlpha  Sep 18  Comment 
NPR  Sep 16  Comment 
In 2006, the World Health Organization issued a report on the "elimination of leprosy as a public health problem." A new report estimates there are still 200,000 new cases a year.
Motley Fool  Sep 15  Comment 
A new study concludes it costs $757 million to develop a new cancer drug, but is that the only reason why drugmakers charge sky-high drug prices or are other reasons to blame, too?
FiercePharma  Sep 13  Comment 
Looking to stand out in an increasingly crowded field of newcomers, Novartis is publishing 5-year data for Cosentyx showing long-term skin clearance in psoriasis patients. The data come as Novartis contends in the next-gen psoriasis space with Eli...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki